Oban Biopharma
Small biotechnology company focused on discovery of GPCR allosteric therapeutics using computational structural analysis and AI-assisted in silico screening of ultra-large compound libraries. Emphasis is on identification and optimization of positive and negative allosteric modulators to improve receptor selectivity and signaling profiles.
Industries
N/A
Services
Computational identification of GPCR allosteric pockets
Structure-based mapping of non-orthosteric binding pockets on GPCRs to guide ligand discovery.
In silico multi-dimensional screening of ultra-large libraries
Screening workflow that evaluates compounds from very large virtual libraries across multiple computational criteria.
AI-based ADME/Tox prediction and prioritization
Use of validated AI predictors to assess absorption, distribution, metabolism, excretion and toxicology properties to maximize chemotype potential.
Medicinal chemistry support for allosteric modulators
Guidance on medicinal chemistry strategies at validated targets informed by computational analyses.
Computational identification of GPCR allosteric pockets
Structure-based mapping of non-orthosteric binding pockets on GPCRs to guide ligand discovery.
In silico multi-dimensional screening of ultra-large libraries
Screening workflow that evaluates compounds from very large virtual libraries across multiple computational criteria.
AI-based ADME/Tox prediction and prioritization
Use of validated AI predictors to assess absorption, distribution, metabolism, excretion and toxicology properties to maximize chemotype potential.
Medicinal chemistry support for allosteric modulators
Guidance on medicinal chemistry strategies at validated targets informed by computational analyses.
Expertise Areas
- GPCR allosteric therapeutics
- Computational structural biology
- AI-assisted drug discovery
- Ultra-large virtual screening
Key Technologies
- Allosteric pocket mapping
- Ultra-large library virtual screening
- AI/ML ADME-Tox prediction
- Computational chemotype analysis